Contact information

* This field is mandatory

Contact details

*
*
*

Company details

*
*
*
*
*
*
*

Inquiry details

By specifying your reason for contact we will be able to provide you with a better service.
*
*
*
*

Sleep and Respiratory

Clinical Study

Connect with us 

Connect with us 

Trial suggests  HOT-HMV therapy can improve outcomes for COPD patients with persistent hypercapnia1

A study evaluating the use of home noninvasive ventilation (NIV) in conjunction with home oxygen therapy (HOT) to treat COPD patients with on-going hypercapnia was investigated in a five-year, multicenter randomized clinical trial of 116 patients in the UK. The Philips co-sponsored study demonstrated a breakthrough for COPD treatment, concluding:

 

Among patients with persistent hypercapnia following an acute exacerbation of COPD, adding home noninvasive ventilation to home oxygen therapy prolonged the median time to re-admission or death from 1.4 months to 4.3 months.1

 

“Patients with severe COPD and persistent hypercapnia have historically had limited therapy options available to them and outcomes have generally been poor,” said Dr. Nicholas Hart, professor and clinical director of Lane Fox Respiratory Service at St. Thomas’ Hospital in London.

 

The trial was designed to investigate a new treatment approach to determine if it could improve outcomes and quality of life for patients with advanced disease. . The results of the five year multi-center study also indicated improved patient health-related quality of life in the first six weeks with the combined treatment.1

 

Continued Dr. Hart: “The trial suggests that combining home oxygen and home non-invasive ventilation therapy can reduce hospital readmissions while maintaining patients’ quality of life, which will drastically change the way we approach COPD treatment worldwide. We are looking forward to hopefully decreasing the mortality and readmission rates that result from severe COPD with further research.”

 

The randomized clinical trial consisted of 116 patients in the United Kingdom was co-sponsored by Philips and carried out by respiratory experts at St. Thomas’ Hospital in London. The results showed that the addition of home NIV prolonged the median time to re-admission or death from 1.4 months to 4.3 months.1

 

 “This study shows that home noninvasive ventilation is a potent, therapeutic tool that clinicians can use to help keep patients with advanced COPD out of the hospital,” said Dr. Teofilo Lee-Chiong Jr., Chief Medical Liaison at Philips. “We hope that this will, in turn, allow them to lead healthier and more active lives at home. These findings add considerably to our knowledge of this highly prevalent and debilitating respiratory disorder, and are expected to greatly influence how clinicians care for patients with COPD on long-term oxygen therapy.”

Philips Respironics Trilogy ventilators

Versatile breath delivery for invasive and noninvasive ventilation

trilogy 100
“This study shows that home noninvasive ventilation is a potent, therapeutic tool that clinicians can use to help keep patients with advanced COPD out of the hospital.”

-Dr. Teofilo Lee-Chiong, pulmonologist and Chief Medical Liaison, Philips

1Murphy PB, et al. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation A Randomized Clinical Trial. JAMA. Published online May 21, 2017. doi:10.1001/jama.2017.4451